<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039206</url>
  </required_header>
  <id_info>
    <org_study_id>MJD MEIR dTMS</org_study_id>
    <secondary_id>0059-13-MMC</secondary_id>
    <nct_id>NCT02039206</nct_id>
  </id_info>
  <brief_title>The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease</brief_title>
  <official_title>The Influence of Deep Repetitive Transcranial Magnetic Stimulation (TMS) on Cerebellar Signs in Patients With Spinocerebellar Ataxia Type 3 (SCA3 - Machado Joseph Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effects of low frequency deep rTMS using the novel HCERMJD-coil on cerebellar
      deficits in patients with SCA3 and to establish its safety in this population.

      Investigator is anticipate that stimulation of the cerebellum with the novel HCERMJD-coil may
      induce significantly therapeutic effects in patients with SCA3 and will pave the way for
      establishing a novel and effective treatment for this disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the Assessment and Rating of Ataxia (SARA)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Machado Joseph Disease (SCA3)</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep TMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep TMS</intervention_name>
    <description>1Hz Stimulation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SCA3 patients aged 20 - 80 years, with detectable clinical signs and confirmed genetic
             diagnosis.

        Exclusion Criteria:

          1. Patients who have concomitant epilepsy.

          2. History of seizure or heat convulsion.

          3. Patients on neuroleptics.

          4. Patients with dementia (MMSE&lt;25) or any unstable medical disorder.

          5. History or current unstable hypertension.

          6. History of head injury or neurosurgical interventions.

          7. History of any metal in the head (outside the mouth).

          8. Known history of any metallic particles in the eye, implanted cardiac pacemaker,
             implanted neurostimulators, surgical clips (above the shoulder line) or any medical
             pumps.

          9. History of frequent or severe headaches.

         10. History of migraine.

         11. History of hearing loss.

         12. History of cochlear implants

         13. History of drug abuse or alcoholism.

         14. Pregnancy or not using a reliable method of birth control.

         15. Participation in current clinical study or clinical study within 30 days prior to this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Gordon, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Machado Joseph disease</keyword>
  <keyword>Deep TMS</keyword>
  <keyword>TMS</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>SCA3</keyword>
  <keyword>Magnetic Stimulation</keyword>
  <keyword>Brainsway</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

